Shingles (Varicella-Zoster Virus - HHV-3)

Overview

Plain-Language Overview

Shingles is a painful skin condition caused by the reactivation of the varicella-zoster virus (VZV), which also causes chickenpox. After a person recovers from chickenpox, the virus remains dormant in nerve cells and can reactivate years later. This reactivation affects the nervous system, specifically the sensory nerves, leading to a painful rash. The rash usually appears as a band or strip on one side of the body or face and is often accompanied by burning pain, itching, and blisters. The condition mainly impacts the skin and nerves, causing discomfort and sometimes long-lasting nerve pain called postherpetic neuralgia. It is more common in older adults and people with weakened immune systems.

Clinical Definition

Shingles, or herpes zoster, is a clinical syndrome caused by the reactivation of latent varicella-zoster virus (VZV) residing in dorsal root or cranial nerve ganglia after primary infection (chickenpox). The core pathology involves viral replication in sensory neurons leading to neuronal inflammation and necrosis, which manifests as a unilateral, dermatomal vesicular rash with associated neuropathic pain. The condition primarily affects the peripheral nervous system and skin, with potential complications including postherpetic neuralgia, secondary bacterial infection, and rarely, neurological sequelae such as cranial nerve palsies or encephalitis. Immunosenescence and immunosuppression are major risk factors for reactivation. Diagnosis is clinically based on the characteristic rash and pain distribution, with confirmatory testing available via PCR or direct fluorescent antibody testing of lesion samples.

Inciting Event

Decline in cell-mediated immunity due to aging or immunosuppression triggers viral reactivation.
Physical or emotional stress can precipitate VZV reactivation.
Local trauma to a dermatome may initiate viral replication in the affected ganglion.
Immunosuppressive therapies such as corticosteroids or chemotherapy can provoke shingles onset.

Latency Period

Latency period spans decades from primary varicella infection to VZV reactivation.
Prodromal symptoms typically develop 1 to 5 days before rash onset.
Vesicular rash appears within days after initial neuropathic pain or dysesthesia.

Diagnostic Delay

Early symptoms of localized neuropathic pain without rash often lead to misdiagnosis as musculoskeletal or nerve pain.
Atypical presentations without classic vesicular rash delay recognition of shingles.
Lack of awareness of shingles in younger or immunocompromised patients can postpone diagnosis.
Misattribution of rash to contact dermatitis or herpes simplex virus infection may delay appropriate treatment.

Patient Population

Older adults, especially those over 60 years, are most commonly affected by shingles.
Immunocompromised patients of any age, including those with HIV/AIDS or on immunosuppressants, have higher incidence.
Individuals with prior varicella infection during childhood or adulthood harbor latent virus.
Both sexes are affected equally without significant gender predilection.

Risk Factors

Advanced age (>50 years) is the strongest risk factor due to waning cell-mediated immunity.
Immunosuppression from HIV, chemotherapy, or immunosuppressive drugs increases reactivation risk.
Stress or trauma can trigger VZV reactivation by transiently impairing immune surveillance.
History of varicella (chickenpox) infection is required as VZV remains latent after primary infection.
Malignancy and chronic diseases like diabetes mellitus increase susceptibility to shingles.

Clinical Presentation

Signs & Symptoms

Prodromal pain, burning, or paresthesia localized to a dermatome precedes rash by 1-3 days.
Development of a painful, unilateral vesicular rash confined to a single dermatome is classic.
Fever and malaise may accompany the rash during the acute phase.
Postherpetic neuralgia causes persistent neuropathic pain after rash resolution.
Ophthalmic involvement can cause eye pain, redness, and visual disturbances.

History of Present Illness

Initial prodrome of burning, tingling, or sharp pain localized to a single dermatome precedes rash by several days.
Development of a unilateral, vesicular rash confined to one or adjacent dermatomes follows prodrome.
Rash progresses from erythematous macules to grouped vesicles on an erythematous base, then crusts over 7 to 10 days.
Associated symptoms include fever, malaise, and headache in some cases.
Pain may persist after rash resolution as postherpetic neuralgia, especially in older adults.

Past Medical History

History of varicella (chickenpox) infection is essential for shingles development.
Immunosuppressive conditions such as HIV/AIDS, cancer, or organ transplantation increase risk.
Use of immunosuppressive medications like corticosteroids or chemotherapy agents predisposes to reactivation.
Chronic illnesses such as diabetes mellitus may impair immune function and increase susceptibility.

Family History

No significant familial inheritance pattern is associated with shingles.
Family history of varicella infection may be present but does not influence reactivation risk.
Genetic predisposition to immune response variability may modulate susceptibility but is not well defined.

Physical Exam Findings

Unilateral, vesicular rash distributed along a single dermatome without crossing the midline is the hallmark finding.
Erythematous base underlying grouped vesicles that evolve into pustules and crusts is typical.
Tender regional lymphadenopathy may be present near the affected dermatome.
Postherpetic neuralgia may cause allodynia or hyperesthesia in the affected area.
Ophthalmic involvement shows vesicular lesions on the eyelid and conjunctiva with possible corneal inflammation.

Physical Exam Maneuvers

Tzanck smear from vesicle base can show multinucleated giant cells but is nonspecific for varicella-zoster virus.
Dermatomal sensory testing helps confirm the distribution of rash and associated neuropathic pain.
Ophthalmologic slit-lamp exam assesses for herpes zoster ophthalmicus complications.
Neurologic exam evaluates for cranial nerve involvement or motor weakness in disseminated cases.

Common Comorbidities

Immunosuppression from HIV, chemotherapy, or corticosteroids increases risk of reactivation.
Older age is associated with higher incidence and severity of shingles.
Diabetes mellitus may predispose to more severe or prolonged disease.
Chronic kidney disease and malignancy are also common comorbid conditions.
History of varicella (chickenpox) infection is a prerequisite for shingles development.

Diagnostic Workup

Diagnostic Criteria

Diagnosis is primarily clinical, based on the presence of a unilateral, painful vesicular rash distributed along a single dermatome. Key findings include prodromal pain or dysesthesia preceding the rash by days, followed by grouped vesicles on an erythematous base. Laboratory confirmation can be obtained by PCR testing of vesicular fluid or skin scrapings to detect VZV DNA, which is the most sensitive and specific test. Direct fluorescent antibody testing or viral culture may also be used but are less sensitive. Serologic testing is not useful for acute diagnosis.

Pathophysiology

Key Mechanisms

Reactivation of latent varicella-zoster virus (VZV) in dorsal root or cranial nerve ganglia causes neuronal inflammation and damage.
Cell-mediated immunity decline with aging or immunosuppression permits VZV reactivation.
Viral replication in sensory nerves leads to dermatomal vesicular rash and neuropathic pain.
Inflammatory response causes nerve edema and damage, resulting in acute neuritis and potential postherpetic neuralgia.
Spread of virus along sensory nerves produces unilateral, dermatomal distribution of lesions without crossing midline.

Involvement	Details
Organs	Skin is the organ manifesting the characteristic painful vesicular rash of shingles.
Organs	Dorsal root ganglia harbor latent varicella-zoster virus and are the site of viral reactivation.
Tissues	Epidermis is the primary site of vesicular rash formation due to viral cytopathic effects.
Tissues	Peripheral nerves are affected by viral reactivation causing neuropathic pain and sensory symptoms.
Cells	T cells mediate the immune response controlling reactivation of latent varicella-zoster virus.
	Dendritic cells present viral antigens to initiate adaptive immunity during shingles.
	Keratinocytes are infected by varicella-zoster virus, leading to characteristic vesicular rash.
Chemical Mediators	Interferon-gamma is produced by activated T cells to inhibit viral replication.
	Tumor necrosis factor-alpha contributes to inflammation and pain in affected skin.
	Substance P is involved in transmitting neuropathic pain signals in postherpetic neuralgia.

Treatments

Pharmacological Treatments

Acyclovir
- Mechanism:
  - Inhibits viral DNA polymerase after phosphorylation by viral thymidine kinase, preventing viral DNA replication
- Side effects:
  - Nephrotoxicity
  - Neurotoxicity
  - Gastrointestinal upset
- Clinical role:
  - First-line
Valacyclovir
- Mechanism:
  - Prodrug of acyclovir with improved oral bioavailability that inhibits viral DNA polymerase
- Side effects:
  - Headache
  - Nausea
  - Renal impairment
- Clinical role:
  - First-line
Famciclovir
- Mechanism:
  - Prodrug converted to penciclovir that inhibits viral DNA polymerase
- Side effects:
  - Headache
  - Diarrhea
  - Fatigue
- Clinical role:
  - First-line
Gabapentin
- Mechanism:
  - Modulates calcium channels to reduce neuropathic pain
- Side effects:
  - Dizziness
  - Somnolence
  - Peripheral edema
- Clinical role:
  - Adjunctive
Capsaicin cream
- Mechanism:
  - Depletes substance P from sensory neurons to reduce pain
- Side effects:
  - Local burning sensation
  - Erythema
- Clinical role:
  - Adjunctive

Non-pharmacological Treatments

Apply cool compresses to affected skin to reduce pain and inflammation.
Maintain skin hygiene and avoid scratching to prevent secondary bacterial infection.
Use loose clothing to minimize irritation of the rash.
Provide patient education on avoiding contact with immunocompromised individuals to prevent transmission.

Prevention

Pharmacological Prevention

Recombinant zoster vaccine (RZV) is the preferred vaccine for adults over 50 to prevent shingles and postherpetic neuralgia.
The live attenuated zoster vaccine (ZVL) is an alternative for immunocompetent adults but less effective than RZV.
Antiviral prophylaxis with acyclovir or valacyclovir may be used in immunocompromised patients to prevent reactivation.
Early treatment with oral antivirals reduces severity and duration but is not preventive once rash appears.

Non-pharmacological Prevention

Avoiding contact with individuals with active varicella or zoster lesions reduces transmission risk.
Maintaining good immune health through nutrition and managing comorbidities lowers reactivation risk.
Screening and managing immunosuppressive conditions can help prevent shingles.
Educating older adults about early symptom recognition promotes prompt treatment.
Proper wound care and hygiene of lesions prevent secondary bacterial infections.

Outcome & Complications

Complications

Postherpetic neuralgia is the most common and debilitating complication causing chronic pain.
Herpes zoster ophthalmicus can lead to keratitis, uveitis, and vision loss.
Disseminated zoster with widespread cutaneous and visceral involvement occurs in immunocompromised patients.
Secondary bacterial infection of skin lesions can cause cellulitis or abscess.
Ramsay Hunt syndrome involves facial nerve palsy with ear vesicles and hearing loss.

Short-term Sequelae	Long-term Sequelae
Acute neuritis causing severe dermatomal pain during rash phase. Cutaneous scarring and pigmentation changes after lesion healing. Secondary bacterial superinfection of vesicles may prolong healing. Transient motor weakness in affected myotomes can occur. Acute herpes zoster ophthalmicus may cause conjunctivitis and keratitis.	Postherpetic neuralgia with persistent neuropathic pain lasting months to years. Chronic scarring and hypo- or hyperpigmentation at rash sites. Vision loss from chronic ocular complications of herpes zoster ophthalmicus. Rarely, zoster paresis with permanent motor deficits. Psychological sequelae including depression and anxiety related to chronic pain.

Differential Diagnoses

Shingles (Varicella-Zoster Virus - HHV-3) versus Herpes Simplex Virus (HSV) Infection

Shingles (Varicella-Zoster Virus - HHV-3)	Herpes Simplex Virus (HSV) Infection
Dermatomal vesicular rash strictly following a single sensory nerve distribution	Grouped vesicles on erythematous base localized to mucocutaneous junctions or orolabial/genital areas
Pain and paresthesia along a dermatome often preceding rash by days	Painful burning or tingling localized to mucocutaneous sites often preceding lesions by hours
Usually a single episode or rare recurrences along same dermatome	Frequent recurrent outbreaks at same mucocutaneous sites
Positive PCR or direct fluorescent antibody test for VZV DNA from lesion	Positive PCR or culture for HSV DNA from lesion swab

Shingles (Varicella-Zoster Virus - HHV-3) versus Contact Dermatitis

Shingles (Varicella-Zoster Virus - HHV-3)	Contact Dermatitis
Grouped vesicles on erythematous base in a dermatomal pattern	Erythematous, edematous plaques with vesicles or bullae often with oozing and crusting
Lesions strictly follow a single sensory dermatome	Lesions correspond to area of allergen or irritant contact, not dermatomal
History of prior varicella infection with reactivation	Recent exposure to known allergen or irritant
Lesions resolve with antiviral therapy over 7-10 days	Lesions improve with allergen avoidance and topical steroids

Shingles (Varicella-Zoster Virus - HHV-3) versus Impetigo

Shingles (Varicella-Zoster Virus - HHV-3)	Impetigo
Vesicular rash with clear fluid progressing to pustules and crusts in dermatomal distribution	Honey-colored crusted erosions primarily on face and extremities
Caused by reactivation of Varicella-Zoster Virus (HHV-3)	Caused by Staphylococcus aureus or Streptococcus pyogenes
More common in older adults or immunocompromised patients	Common in young children
Requires antiviral agents such as acyclovir	Responds to topical or oral antibiotics

Shingles (Varicella-Zoster Virus - HHV-3) versus Dermatomal Eczema Herpeticum

Shingles (Varicella-Zoster Virus - HHV-3)	Dermatomal Eczema Herpeticum
Reactivation of latent VZV in dorsal root ganglia	Disseminated HSV infection in patients with atopic dermatitis
Localized vesicular rash confined to a single dermatome	Widespread vesiculopustular eruption often beyond dermatomal boundaries
Occurs in immunocompetent or immunocompromised hosts with prior varicella	Occurs in patients with impaired skin barrier and atopic dermatitis
Positive VZV PCR from lesions	Positive HSV PCR from lesions